Thanks for the reply. The pre-clinical results the company had shared previously (years ago perhaps- no longer in their corp presentation), showed better results with the NSS + Cells, compared to just the NSS alone. So I do agree that may be ultimately where this therapy is headed in the very long term (years), IF NVIV can get the NSS approved first.
I still believe there is value in the science/technology/IP but the Management execution has been terrible. I was one of Perrin's cheerleaders for awhile but it's clear he has failed on multiple fronts.
Toselli, in my opinion, is the type of leader this company needs now. His experience in getting devices through the FDA minefield is what we need. Additionally, his experience at JNJ and his potential connections there (and potentially elsewhere), may help the company form some type of strategic partnerships down the road.
Best of luck to all longs and if you're short, congrats, you've made a killing!
News 
Market Data 
Discover 
